214 related articles for article (PubMed ID: 32284379)
1. Novel Ionophores Active against La Crosse Virus Identified through Rapid Antiviral Screening.
Sandler ZJ; Firpo MR; Omoba OS; Vu MN; Menachery VD; Mounce BC
Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32284379
[TBL] [Abstract][Full Text] [Related]
2. The La Crosse virus class II fusion glycoprotein
Thannickal SA; Spector SN; Stapleford KA
J Virol; 2023 Aug; 97(8):e0081923. PubMed ID: 37578236
[TBL] [Abstract][Full Text] [Related]
3. Rottlerin inhibits La Crosse virus-induced encephalitis in mice and blocks release of replicating virus from the Golgi body in neurons.
Ojha D; Winkler CW; Leung JM; Woods TA; Chen CZ; Nair V; Taylor K; Yeh CD; Tawa GJ; Larson CL; Zheng W; Haigh CL; Peterson KE
Nat Microbiol; 2021 Nov; 6(11):1398-1409. PubMed ID: 34675384
[TBL] [Abstract][Full Text] [Related]
4. Enhancement of infectivity of insect cell-derived La Crosse Virus by human serum.
Cruz MA; Parks GD
Virus Res; 2021 Jan; 292():198228. PubMed ID: 33188797
[TBL] [Abstract][Full Text] [Related]
5. La Crosse virus infectivity, pathogenesis, and immunogenicity in mice and monkeys.
Bennett RS; Cress CM; Ward JM; Firestone CY; Murphy BR; Whitehead SS
Virol J; 2008 Feb; 5():25. PubMed ID: 18267012
[TBL] [Abstract][Full Text] [Related]
6. Polyamine Depletion Inhibits Bunyavirus Infection via Generation of Noninfectious Interfering Virions.
Mastrodomenico V; Esin JJ; Graham ML; Tate PM; Hawkins GM; Sandler ZJ; Rademacher DJ; Kicmal TM; Dial CN; Mounce BC
J Virol; 2019 Jul; 93(14):. PubMed ID: 31043534
[TBL] [Abstract][Full Text] [Related]
7. A recombinant chimeric La Crosse virus expressing the surface glycoproteins of Jamestown Canyon virus is immunogenic and protective against challenge with either parental virus in mice or monkeys.
Bennett RS; Gresko AK; Nelson JT; Murphy BR; Whitehead SS
J Virol; 2012 Jan; 86(1):420-6. PubMed ID: 22013033
[TBL] [Abstract][Full Text] [Related]
8. Age-dependent myeloid dendritic cell responses mediate resistance to la crosse virus-induced neurological disease.
Taylor KG; Woods TA; Winkler CW; Carmody AB; Peterson KE
J Virol; 2014 Oct; 88(19):11070-9. PubMed ID: 25008929
[TBL] [Abstract][Full Text] [Related]
9. Orthobunyavirus entry into neurons and other mammalian cells occurs via clathrin-mediated endocytosis and requires trafficking into early endosomes.
Hollidge BS; Nedelsky NB; Salzano MV; Fraser JW; González-Scarano F; Soldan SS
J Virol; 2012 Aug; 86(15):7988-8001. PubMed ID: 22623766
[TBL] [Abstract][Full Text] [Related]
10. Targeted Mutations in the Fusion Peptide Region of La Crosse Virus Attenuate Neuroinvasion and Confer Protection against Encephalitis.
Hollidge BS; Salzano MV; Ibrahim JM; Fraser JW; Wagner V; Leitner NE; Weiss SR; Weber F; González-Scarano F; Soldan SS
Viruses; 2022 Jul; 14(7):. PubMed ID: 35891445
[TBL] [Abstract][Full Text] [Related]
11. La Crosse Virus Infection of Human Keratinocytes Leads to Interferon-Dependent Apoptosis of Bystander Non-Infected Cells In Vitro.
Cruz MA; Parks GD
Viruses; 2020 Feb; 12(3):. PubMed ID: 32106552
[TBL] [Abstract][Full Text] [Related]
12. Double Crossed: A Case of La Crosse Encephalitis.
Ding A; Shen B; Elliott S; Joshi K; Coghlin D; McLaughlin S
R I Med J (2013); 2020 Apr; 103(3):59-62. PubMed ID: 32236166
[TBL] [Abstract][Full Text] [Related]
13. The La Crosse virus class II fusion glycoprotein
Thannickal SA; Spector SN; Stapleford KA
bioRxiv; 2023 Feb; ():. PubMed ID: 36865275
[TBL] [Abstract][Full Text] [Related]
14. La Crosse Virus Disease in the United States, 2003-2019.
Vahey GM; Lindsey NP; Staples JE; Hills SL
Am J Trop Med Hyg; 2021 Jul; 105(3):807-812. PubMed ID: 34280142
[TBL] [Abstract][Full Text] [Related]
15. Elongin C Contributes to RNA Polymerase II Degradation by the Interferon Antagonist NSs of La Crosse Orthobunyavirus.
Schoen A; Lau S; Verbruggen P; Weber F
J Virol; 2020 Mar; 94(7):. PubMed ID: 31941775
[TBL] [Abstract][Full Text] [Related]
16. The CARD9-Associated C-Type Lectin, Mincle, Recognizes La Crosse Virus (LACV) but Plays a Limited Role in Early Antiviral Responses against LACV.
Monteiro JT; Schön K; Ebbecke T; Goethe R; Ruland J; Baumgärtner W; Becker SC; Lepenies B
Viruses; 2019 Mar; 11(3):. PubMed ID: 30917612
[TBL] [Abstract][Full Text] [Related]
17. Effect of mixed infections of Sindbis and La Crosse viruses on replication of each virus in vitro.
Bara JJ; Muturi EJ
Acta Trop; 2014 Feb; 130():71-5. PubMed ID: 24463260
[TBL] [Abstract][Full Text] [Related]
18. Age influences susceptibility of brain capillary endothelial cells to La Crosse virus infection and cell death.
Basu R; Nair V; Winkler CW; Woods TA; Fraser IDC; Peterson KE
J Neuroinflammation; 2021 Jun; 18(1):125. PubMed ID: 34082753
[TBL] [Abstract][Full Text] [Related]
19. Comparative sequence analyses of La Crosse virus strain isolated from patient with fatal encephalitis, Tennessee, USA.
Lambert AJ; Fryxell RT; Freyman K; Ulloa A; Velez JO; Paulsen D; Lanciotti RS; Moncayo A
Emerg Infect Dis; 2015 May; 21(5):833-6. PubMed ID: 25898269
[TBL] [Abstract][Full Text] [Related]
20. Epidemiology of La Crosse Virus Emergence, Appalachia Region, United States.
Bewick S; Agusto F; Calabrese JM; Muturi EJ; Fagan WF
Emerg Infect Dis; 2016 Nov; 22(11):1921-1929. PubMed ID: 27767009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
